These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36590263)

  • 1. Design and Synthesis of Neutralizable Fondaparinux.
    Zhang L; Liu Y; Xu Z; Hao T; Wang PG; Zhao W; Li T
    JACS Au; 2022 Dec; 2(12):2791-2799. PubMed ID: 36590263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives.
    Bianchini EP; Fazavana J; Picard V; Borgel D
    Blood; 2011 Feb; 117(6):2054-60. PubMed ID: 21048158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity.
    Fazavana J; Bianchini EP; Saller F; Smadja C; Picard V; Taverna M; Borgel D
    J Thromb Haemost; 2013 Jun; 11(6):1128-36. PubMed ID: 23581397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues.
    Zhou Z; Zhang L; Wu X; Luo L; Wu J; Xu D; Wu M
    Eur J Med Chem; 2022 Apr; 234():114256. PubMed ID: 35279609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silver-assisted gold-catalyzed formal synthesis of the anticoagulant Fondaparinux pentasaccharide.
    Walke G; Kasdekar N; Sutar Y; Hotha S
    Commun Chem; 2021 Feb; 4(1):15. PubMed ID: 36697540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis.
    Kaeberich A; Raaz U; Vogt A; Maedgefessel L; Neuhart E; Krezel C; Drouget L; Hauroeder B; Buerke M; Werdan K; Schlitt A
    J Thromb Thrombolysis; 2014; 37(2):118-30. PubMed ID: 23821043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants.
    Shenoi RA; Kalathottukaren MT; Travers RJ; Lai BF; Creagh AL; Lange D; Yu K; Weinhart M; Chew BH; Du C; Brooks DE; Carter CJ; Morrissey JH; Haynes CA; Kizhakkedathu JN
    Sci Transl Med; 2014 Oct; 6(260):260ra150. PubMed ID: 25355700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of the heparin-based anticoagulant drug fondaparinux.
    Chang CH; Lico LS; Huang TY; Lin SY; Chang CL; Arco SD; Hung SC
    Angew Chem Int Ed Engl; 2014 Sep; 53(37):9876-9. PubMed ID: 25044485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of Anticoagulant Pentasaccharide Fondaparinux via 3,5-Dimethyl-4-(2'-phenylethynylphenyl)phenyl Glycosides.
    Liu W; Hu Z; Xu P; Yu B
    Org Lett; 2023 Dec; 25(47):8506-8510. PubMed ID: 37983186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
    Siddiqui F; Tafur A; Bontekoe E; Iqbal O; Jeske W; Mehrotra S; Hoppensteadt D; Ramacciotti E; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029619895120. PubMed ID: 31914798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total synthesis of anticoagulant pentasaccharide fondaparinux.
    Li T; Ye H; Cao X; Wang J; Liu Y; Zhou L; Liu Q; Wang W; Shen J; Zhao W; Wang P
    ChemMedChem; 2014 May; 9(5):1071-80. PubMed ID: 24729477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay.
    Bourti Y; Fazavana J; Armand M; Saller F; Lasne D; Borgel D; Bianchini EP
    Thromb Haemost; 2016 Aug; 116(3):452-60. PubMed ID: 27412396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An efficient anticoagulant candidate: Characterization, synthesis and in vivo study of a fondaparinux analogue Rrt1.17.
    Zhang GQ; Jin H; Zhao Y; Guo L; Gao X; Wang X; Tie S; Shen J; Wang PG; Gan H; Cui H; Zhao W
    Eur J Med Chem; 2017 Jan; 126():1039-1055. PubMed ID: 28012344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmable One-Pot Synthesis of Heparin Pentasaccharide Fondaparinux.
    Dey S; Lo HJ; Wong CH
    Org Lett; 2020 Jun; 22(12):4638-4642. PubMed ID: 32496799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Porous Polymers as Universal Reversal Agents for Heparin Anticoagulants through an Inclusion-Sequestration Mechanism.
    Lin F; Yu SB; Liu YY; Liu CZ; Lu S; Cao J; Qi QY; Zhou W; Li X; Liu Y; Tian J; Li ZT
    Adv Mater; 2022 Jun; 34(23):e2200549. PubMed ID: 35499202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study.
    Gueret P; Combe S; Krezel C; Fuseau E; van Giersbergen PL; Petitou M; Neuhart E
    Eur J Clin Pharmacol; 2017 Jan; 73(1):15-28. PubMed ID: 27742998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
    Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
    Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemistry and clinical pharmacology of new anticoagulant agents.
    Samama MM; Gerotziafas GT; Elalamy I; Horellou MH; Conard J
    Pathophysiol Haemost Thromb; 2002; 32(5-6):218-24. PubMed ID: 13679646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux (Arixtra): a new anticoagulant.
    Giangrande PL
    Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.